

Specialty Pharmacy Program

Xgeva™ (denosumab)

DESCRIPTION

Xgeva is a RANK ligand (RANKL) inhibitor indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Xgeva is not indicated for the prevention of SREs in patients with multiple myeloma.

APPROVAL DURATION

Approval duration: 1 year

APPROVAL CRITERIA

Xgeva will be approved if the patient meets the following criteria:

- I. Patient has documented bone metastases from a solid tumor cancer **AND**
- II. Patient does not have multiple myeloma **AND**
- III. Patient does not have pre-existing hypocalcemia **OR**
- IV. Patient will have hypocalcemia corrected prior to starting Xgeva **AND**
- V. Patient will receive calcium and vitamin D as needed to prevent hypocalcemia.